First-inHuman Clinical Trial of Oral ONC 201 in Patients with Refractory Solid Tumors

[1]  Michael L. Wang,et al.  ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies , 2016, Science Signaling.

[2]  W. El-Deiry,et al.  ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases , 2016, Science Signaling.

[3]  W. El-Deiry,et al.  First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent , 2015, PloS one.

[4]  W. El-Deiry,et al.  Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway , 2015, Molecular Cancer.

[5]  E. Messaris,et al.  Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects , 2013, Science Translational Medicine.

[6]  G. Kramer,et al.  Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles , 2006, British Journal of Cancer.

[7]  I. Ercan,et al.  Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study , 2006, Cancer investigation.

[8]  G. Kramer,et al.  Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18 , 2004, Cancer Research.

[9]  J. Wood,et al.  A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera , 2003, Apoptosis.

[10]  S. Linder,et al.  Measurement of an apoptotic product in the sera of breast cancer patients. , 2003, European journal of cancer.

[11]  M. Markianos,et al.  Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol , 2001, European Archives of Psychiatry and Clinical Neuroscience.

[12]  R Simon,et al.  Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.